Earnings Releases·Nov 3, 2026, 4:10 PM ET

Alamar Biosciences — Third Quarter 2026 Earnings Summary

Total revenue surged 68% year-over-year to $33.5 million, driven by double-digit growth across instruments, consumables, and services, while gross margin expanded to 61.5% despite an 81% increase in operating expenses.
Full-year 2026 revenue guidance was raised to $121 million–$123 million, reflecting a 64% growth midpoint compared to 2025, as biopharma customers became the largest revenue segment for the first time.
Strategic momentum accelerated with a UK Biobank partnership for 80,000 samples and a GSK collaboration for a 60,000-sample study, alongside the first longitudinal Alzheimer's treatment data published in *Lancet Neurology*.
Balance sheet strength improved significantly with $231.5 million in total cash and investments, the elimination of all term debt and convertible preferred stock, and a shift to positive stockholders' equity of $303.7 million.
President Tod White will retire at year-end but will serve as an advisor through June 2027, following his leadership of the company through its IPO.